69 related articles for article (PubMed ID: 16033083)
1. Further evidence for prolongation of survival of pancreatic cancer patients by efficacy orientated sequential polychemotherapy (EOSPC) based on serial tumor marker determinations (CA 19-9/CEA).
Klapdor R; Bahlo M; Babinsky A
Anticancer Res; 2005; 25(3A):1687-91. PubMed ID: 16033083
[TBL] [Abstract][Full Text] [Related]
2. Reflections on treatment strategies for palliative chemotherapy of pancreatic cancer.
Klapdor R; Bahlo M; Babinsky A; Brenzinger ML
Anticancer Res; 2007; 27(4A):1789-94. PubMed ID: 17649774
[TBL] [Abstract][Full Text] [Related]
3. Sequential polychemotherapy in exocrine pancreatic cancer.
Klapdor R; Bahlo M; Babinski A; Broemel T; Müller C; Seutter R
Anticancer Res; 2003; 23(2A):841-4. PubMed ID: 12820310
[TBL] [Abstract][Full Text] [Related]
4. Improvement of survival by efficacy orientated sequential polychemotherapy of exocrine pancreatic cancer.
Klapdor R; Müller C; Seutter R; Bahlo M; Peters W; Fenner C
Anticancer Res; 2000; 20(6D):5201-7. PubMed ID: 11326695
[TBL] [Abstract][Full Text] [Related]
5. CA19-9 serum concentrations--analysis of the serum kinetics during first-line therapy of pancreatic cancer in relation to overall survival.
Klapdor R; Bahlo M; Babinski A; Klapdor S
Anticancer Res; 2010 May; 30(5):1869-74. PubMed ID: 20592394
[TBL] [Abstract][Full Text] [Related]
6. Tumor markers in evaluating the response to radiotherapy in unresectable pancreatic cancer.
Okusaka T; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
Hepatogastroenterology; 1998; 45(21):867-72. PubMed ID: 9684148
[TBL] [Abstract][Full Text] [Related]
7. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
8. Response to a third-line mitomycin C (MMC)-based chemotherapy in a patient with metastatic pancreatic adenocarcinoma carrying germline BRCA2 mutation.
Chalasani P; Kurtin S; Dragovich T
JOP; 2008 May; 9(3):305-8. PubMed ID: 18469443
[TBL] [Abstract][Full Text] [Related]
9. [Role of the tumor markers CA 19-9 and carcinoembryonic antigen (CEA) in diagnosis, treatment and prognosis of pancreatic cancer].
Kokhanenko NIu; Ignashov AM; Varga EV; Polkanova MS; Aleshina LA; Kimbarovskaia AA; Osipenko SK; Lebedev EG
Vopr Onkol; 2001; 47(3):294-7. PubMed ID: 11544826
[TBL] [Abstract][Full Text] [Related]
10. CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer.
Ishii H; Okada S; Sato T; Wakasugi H; Saisho H; Furuse J; Ishikawa O; Matsuno S; Yokoyama S
Hepatogastroenterology; 1997; 44(13):279-83. PubMed ID: 9058159
[TBL] [Abstract][Full Text] [Related]
11. Preoperative serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels for the evaluation of curability and resectability in patients with pancreatic adenocarcinoma.
Fujioka S; Misawa T; Okamoto T; Gocho T; Futagawa Y; Ishida Y; Yanaga K
J Hepatobiliary Pancreat Surg; 2007; 14(6):539-44. PubMed ID: 18040617
[TBL] [Abstract][Full Text] [Related]
12. Locoregional/systemic chemotherapy of locally advanced/metastasized pancreatic cancer with a combination of mitomycin-C and gemcitabine and simultaneous follow-up by imaging methods and tumor markers.
Klapdor R; Seutter E; Lang-Pölckow EM; Reichle H; Hinrichs A
Anticancer Res; 1999; 19(4A):2459-69. PubMed ID: 10470175
[TBL] [Abstract][Full Text] [Related]
13. Atypical courses of serum tumor markers--4 case reports.
Klapdor R; Bahlo M; Babinski A
Anticancer Res; 2003; 23(2A):845-50. PubMed ID: 12820311
[TBL] [Abstract][Full Text] [Related]
14. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies.
Mehta J; Prabhu R; Eshpuniyani P; Kantharia C; Supe A
Trop Gastroenterol; 2010; 31(3):190-4. PubMed ID: 21560524
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with gemcitabine (GEM) and erlotinib (E) in exocrine pancreatic cancer under special reference to RASH and the tumour marker CA19-9.
Klapdor R; Klapdor S; Bahlo M
Anticancer Res; 2012 May; 32(5):2191-7. PubMed ID: 22593509
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: role of CEA and CA 19-9.
Weissenberger C; Von Plehn G; Otto F; Barke A; Momm F; Geissler M
Anticancer Res; 2005; 25(3A):1787-93. PubMed ID: 16033101
[TBL] [Abstract][Full Text] [Related]
17. Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.
Park YA; Sohn SK; Seong J; Baik SH; Lee KY; Kim NK; Cho CW
J Surg Oncol; 2006 Feb; 93(2):145-50. PubMed ID: 16425302
[TBL] [Abstract][Full Text] [Related]
18. [Treatment of the unresectable non small cell lung carcinoma].
Spásová I
Cas Lek Cesk; 2005; 144(9):602-12; discussion 612-3. PubMed ID: 16193938
[TBL] [Abstract][Full Text] [Related]
19. Limited value of CA 19-9 in predicting early treatment failure in patients with advanced pancreatic cancer.
Vormittag L; Gleiss A; Scheithauer W; Lang F; Laengle F; Kornek GV
Oncology; 2009; 77(2):140-6. PubMed ID: 19628952
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
